Product NDC: | 0186-0322 |
Proprietary Name: | ATACAND HCT |
Non Proprietary Name: | Candesartan cilexetil and Hydrochlorothiazide |
Active Ingredient(s): | 32; 12.5 mg/1; mg/1 & nbsp; Candesartan cilexetil and Hydrochlorothiazide |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0186-0322 |
Labeler Name: | AstraZeneca LP |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021093 |
Marketing Category: | NDA |
Start Marketing Date: | 20000928 |
Package NDC: | 0186-0322-28 |
Package Description: | 100 TABLET in 1 CARTON (0186-0322-28) |
NDC Code | 0186-0322-28 |
Proprietary Name | ATACAND HCT |
Package Description | 100 TABLET in 1 CARTON (0186-0322-28) |
Product NDC | 0186-0322 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Candesartan cilexetil and Hydrochlorothiazide |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20000928 |
Marketing Category Name | NDA |
Labeler Name | AstraZeneca LP |
Substance Name | CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE |
Strength Number | 32; 12.5 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Angiotensin 2 Receptor Antagonists [MoA],Angiotensin 2 Receptor Blocker [EPC],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient] |